Lenalidomida Tecnigen

Lenalidomide, the active ingredient in Lenalidomida Tecnigen, is an immunomodulatory agent presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma.

GNH USA supplies Lenalidomida Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Customers benefit from reliable logistics and responsive technical support throughout the supply chain.

Lenalidomide is indicated for several hematologic malignancies and related disorders.

- Multiple Myeloma: improves progression‑free survival and overall response in patients with relapsed or refractory disease. - Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: used in combination regimens to achieve disease control in relapsed cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count leading to infection risk. - Thrombocytopenia: low platelet levels causing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Nausea: gastrointestinal upset often mild. - Diarrhea: loose stools that may require hydration.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers during therapy. - Hepatotoxicity: elevated liver enzymes or liver failure.

Prior to initiating Lenalidomida Tecnigen, several safety considerations should be reviewed. - Pregnancy: contraindicated (Category X); ensure effective contraception for both patient and partner. - Thrombosis risk: assess history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. - Renal impairment: adjust dose in patients with reduced creatinine clearance. - Hepatic impairment: use caution and monitor liver function tests. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomida Tecnigen can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): may raise lenalidomide levels. - Strong CYP3A4 inducers (rifampin, carbamazepine): may lower drug exposure. - Anticoagulants (warfarin): increased bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (midazolam, cyclosporine): monitor concentrations. - Live vaccines: avoid due to immunosuppression.